Talk Lecture track
The Metabolic Dysfunction–Associated Steatotic Liver Disease and Hepatocellular Carcinoma Continuum: Fibrosis, Inflammation, and Clinical Decision-Making, Part 2
Fri, Nov 6, 2026 · 2:00–3:30 PM MST Convention Center: Bluebird Ballroom 1A, Colorado Convention Center
About this session
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a leading driver of fibrosis progression and hepatocellular carcinoma (HCC), with implications that extend beyond the liver. This joint session traces the clinical continuum from MASLD/metabolic dysfunction–associated steatohepatitis (MASH) to liver cancer, highlighting how metabolic inflammation, fibrosis, and comorbidity shape cancer risk, prevention, and treatment.
Speakers
-
University of Michigan Medical Center
Chair
-
Mayo Clinic Rochester
Chair
-
SBP Discovery
Speaker
-
Massachusetts General Hospital
Speaker
-
Speaker
Reviews of this session
No reviews yet
Were you in the room? Reviews are open until Nov 9, 2027.